A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Key facts

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Principal Investigator

Li Feng, Ph.D.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Intervention

Yishen Qutong Granules(drug)

Enrollment

536 enrolled

Eligibility

18-80 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, Chaoyang, China

Collaborators

China-Japan Friendship Hospital · Shanxi Province Cancer Hospital · Changzhi People's Hospital · Yuncheng Central Hospital · Jilin Provincial Tumor Hospital · Liaoning Cancer Hospital & Institute · Shanghai Chest Hospital · The Affiliated Hospital of Qingdao University · Zhejiang Cancer Hospital · Henan Cancer Hospital · The First Affiliated Hospital of Zhengzhou University · Wuhan No.1 Hospital · Anyang Tumor Hospital · Chongqing University Cancer Hospital · Mianyang Central Hospital · The Second Affiliated Hospital of Harbin Medical University · The First Hospital of Jilin University · Tianjin Medical University Cancer Institute and Hospital · Sichuan Cancer Hospital and Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07331155
  A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
  Nanjing Leads Biolabs Co.,Ltd
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc

See all trials for Squamous cell carcinoma of the esophagus →